Methods of administering anti-fibrotic therapy
US-11207304-B2 · Dec 28, 2021 · US
Methods of administering anti-fibrotic therapy
US11925624B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11925624-B2 |
| Application number | US-202117528537-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 17, 2021 |
| Priority date | Nov 30, 2016 |
| Publication date | Mar 12, 2024 |
| Grant date | Mar 12, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of providing Compound I therapy to a subject in need thereof: comprising: evaluating the renal function of the subject; and then administering a therapeutically effective amount of Compound I to the subject. 2. The method of claim 1 , wherein evaluating the renal function of the subject comprises determining the subject's creatinine clearance rate. 3. The method of claim 2 , wherein the subject has a creatinine clearance of ≥90 mL/min. 4. The method of claim 2 , wherein the subject has a creatinine clearance of 60-89 mL/min. 5. The method of claim 2 , wherein the subject has a creatinine clearance of 30-59 mL/min and <50 mL/min. 6. The method of claim 2 , wherein the subject has a creatinine clearance of 15-29 mL/min. 7. The method of claim 1 , wherein the subject does not have end stage renal disease requiring dialysis. 8. The method of claim 1 , further comprising monitoring changes in the subject's serum creatinine (Scr) level after said administering of Compound I. 9. The method of claim 8 , further comprising adjusting the amount of Compound I or discontinuing Compound I therapy after monitoring changes in the subject's Scr level. 10. The method of claim 8 , further comprising advising the subject to discontinue Compound I therapy when the subject's Scr level is 1.5 times baseline or higher, or shows a ≥0.3 mg/dL (≥26.5 μmol/L) increase. 11. The method of claim 1 , wherein the subject is suffering from a fibrotic disorder. 12. The method of claim 11 , wherein the subject is suffering from idiopathic pulmonary fibrosis (IPF).
Assignees
Inventors
Classifications
- A61K31/437Primary
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
- A61K31/4355Primary
the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom · CPC title
Drugs for disorders of the respiratory system · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11925624B2 cover?
- The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.
- Who is the assignee on this patent?
- Genentech Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/437. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).